Screener
CareDx CDNA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by CareDx in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: CareDx’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001217234-26-000033
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Taxes paid related to net share settlement of restricted stock units | (2,511) | (3,065) |
| Proceeds from exercise of stock options | 109 | 3,049 |
| Payment of contingent consideration | (1,500) | (1,500) |
| Net cash used in financing activities | (2,911) | (643) |
| Effect of exchange rate changes on cash and cash equivalents | 13 | (77) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 12,494 | (25,979) |
| Cash, cash equivalents and restricted cash at beginning of period | 65,980 | 115,274 |
| Cash, cash equivalents and restricted cash at end of period | $78,474 | $89,295 |
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is CareDx's cash & equivalents?
- CareDx (CDNA) reported cash & equivalents of $78.47M in Q1 2026.
- How has CareDx's cash & equivalents changed year-over-year?
- CareDx's cash & equivalents decreased by 12.1% year-over-year, from $89.3M to $78.47M.
- What is the long-term trend for CareDx's cash & equivalents?
- Over 5 years (2020 to 2025), CareDx's cash & equivalents has grown at a -13.3% compound annual growth rate (CAGR), from $134.94M to $65.98M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about CareDx's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude